All In MedTech

Device Trial Radar · NCT05822232

FreeStyle Libre 2 Discharge Trial

A Randomized Controlled Trial Comparing the FreeStyle Libre 2 Continuous Glucose Monitoring vs Point of Care Glucose Testing for the Management of Subjects With Type 2 Diabetes After Hospital Discharge: FreeStyle Libre 2 Discharge Trial

Last checked: Nov 20, 2026Latest source record: Apr 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

100

Planned (sponsor's estimate)

Start

Aug 17, 2022

Primary completion

Apr 30, 2024

Study completion Apr 30, 2024

Sponsor

Lead sponsor
Palo Alto Medical FoundationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Abbott Diabetes Care; Emory University
First posted
Apr 20, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn about the benefits of using aa Continuous Glucose Monitoring (CGM) system in patients with diabetes following discharge from the hospital. The main question it aims to answer is: • If the use of CGM with alarms is safe and effective for managing low and/or high blood sugars when compared with performing finger sticks several times per day Participants will wear one or two FreeStyle Libre CGM sensors for 12-14 days three times over a 12-week (3 month) period. This means that they will have the one to two sensors inserted under their skin. They will be asked to come to the study site four times and complete two phone calls with research staff over the 12-week period. Researchers will compare the LibreView CGM group to the Standard of Care group to see if the use of continuous glucose monitoring (CGM) reduces risk of low blood sugar in patients with type 2 diabetes (T2D) after hospital discharge when compared with the current standard method.

Conditions

  • Diabetes Mellitus, Type 2
  • Hypoglycemia

Interventions

  • FreeStyle Libre 2 CGMDevice

    FreeStyle Libre 2 CGM is FDA-approved and will be used according to FDA-approved labeling

  • FreeStyle Libre Pro blinded CGMDevice

    FreeStyle Libre Pro blinded CGM is FDA-approved and will be used according to FDA-approved labeling

  • FreeStyle Precision Neo blood glucose meterDevice

    FreeStyle Precision Neo blood glucose meter is FDA-approved and will be used according to FDA-approved labeling

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety EndpointTime frame: 2 weeks

5 more outcomes with a free account

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Palo Alto Medical Foundation Research Institute

    Palo Alto, California · Recruiting

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.